非肾非神经精神性系统性红斑狼疮安慰剂应答的系统综述与汇总分析
该系统综述纳入24项非肾非神经精神性SLE的II/III期生物制剂随机对照试验,共11128例患者,其中安慰剂组3899例。汇总分析显示安慰剂组主要终点应答率为36.2%,SRI-4应答率39.8%,SRI-5、SRI-6和BILAG-BICLA应答率分别为29.2%、28.4%和30.9%。
要点
- 非肾非神经精神性SLE试验中安慰剂联合标准治疗的主要终点应答率超过三分之一。
- SRI-4应答率较高(39.8%),终点越严格应答率越低(SRI-5 29.2%,SRI-6 28.4%)。
- 安慰剂组严重不良事件16.3%,严重感染5.5%,死亡0.56%。
核心结论
- 在非肾非神经精神性SLE生物制剂随机对照试验中,超过三分之一的安慰剂联合标准治疗患者达到各自主要终点。
- 某些终点如SRI-4的安慰剂应答率更高,而更严格的终点应答率降低。
研究设计与样本
- 系统综述与汇总分析,检索PubMed数据库2000年至2019年12月发表的II/III期随机对照试验。
- 纳入评估生物制剂治疗非肾非神经精神性SLE疗效与安全性的RCT,共24项,总计11128例患者。
- 收集安慰剂治疗患者(n=3899)的疗效与安全性数据,采用描述性统计。
主要发现
- 安慰剂组患者93.5%为女性,60.2%为高加索人,平均年龄39.7岁,平均病程7.4年。
- 安慰剂组平均初始SLEDAI 2000为10.4,60.5%抗dsDNA抗体阳性,41.9%补体C3降低,35.6%补体C4降低。
- 标准治疗包括糖皮质激素(85.9%)、抗疟药(72.8%)和免疫抑制剂(48.5%)。
- 安慰剂组主要终点应答率36.2%,SRI-4应答率39.8%,SRI-5应答率29.2%,SRI-6应答率28.4%,BILAG-BICLA应答率30.9%。
- 安全性方面,严重不良事件发生率16.3%,严重感染5.5%,恶性肿瘤0.3%,死亡0.56%。
关键数值与推荐
- 主要终点应答率36.2%(安慰剂组,n=3899,定义依据各研究)。
- SRI-4应答率39.8%,SRI-5应答率29.2%,SRI-6应答率28.4%。
- BILAG-based Combined Lupus Assessment应答率30.9%。
- 严重不良事件16.3%,严重感染5.5%,恶性肿瘤0.3%,死亡0.56%。
临床怎么用
- 解读非肾非神经精神性SLE生物制剂RCT时需考虑较高的安慰剂应答率,尤其是SRI-4等复合终点。
- 试验设计应关注终点严格程度对安慰剂应答率的影响,更严格终点可能降低安慰剂应答。
- 安慰剂组的安全性数据可为评估生物制剂额外风险提供参照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Most randomized controlled trials (RCTs) in SLE have failed to reach their respective end points, with the rates of response to placebo (plus standard-of-care treatment) being unexpectedly high. The aim of this systematic review was to quantify the response to placebo in non-renal, non-neuropsychiatric lupus. METHODS: The PubMed database was searched (from 2000 to December 2019) for phase II/III RCTs assessing the efficacy and safety of biologics in non-renal, non-neuropsychiatric SLE. Data on the efficacy and safety of the placebo-treated patients were collected in a pre-established data retrieval form. Descriptive statistics were used. RESULTS: A total of 24 RCTs (n = 11128 in total) were included. Placebo-treated patients (n = 3899) were mostly females (93.5%), Caucasians (60.2%), of mean age 39.7 years, and having a mean disease duration of 7.4 years. Their mean initial SLEDAI 2000 was 10.4, whereas 60.5% had positive anti-dsDNA antibodies, 41.9% low C3 and 35.6% low C4 at randomization. Standard-of-care treatment included glucocorticosteroids in 85.9%, antimalarials in 72.8% and immunosuppressives in 48.5%. The response to placebo was 36.2% for the primary end point (as defined in each study), 39.8% for the SLE Responder Index-4 (SRI-4), 29.2% for SRI-5, 28.4% for SRI-6 and 30.9% for BILAG-based Combined Lupus Assessment response. Regarding safety, there were serious adverse events in 16.3% of patients, serious infections in 5.5% and malignancies in 0.3%, and death occurred in 0.56% of patients. CONCLUSION: More than one-third of the placebo-treated patients achieved their respective primary end points in RCTs with biologics in non-renal, non-neuropsychiatric SLE. The response rate was higher for certain end points, such as the SRI-4, while it decreased with more stringent end points.
引用
- Tselios K, Wakani L, Gladman DD, et al. Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. Rheumatology (Oxford). 2021. PMID: 33140092. doi:10.1093/rheumatology/keaa655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。